Tedizolid phosphate.

Area of Science:

• Pharmacology
• Drug Information Services
• Health Systems Pharmacy

Background:

• Pharmacy & Therapeutics (P&T) Committees require timely and accurate drug information.
• New drug approvals and late-stage trials necessitate comprehensive evaluations.
• Effective medication use evaluations (MUEs) are crucial for patient safety and cost management.

Purpose of the Study:

• To describe the offerings of The Formulary Monograph Service.
• To highlight the value of monthly drug monographs and DUE/MUEs for healthcare professionals.
• To inform subscribers about the scope and accessibility of the service.

Main Methods:

• Dissemination of 5-6 detailed monographs on new or late-phase drugs monthly.
• Provision of 1-page summary monographs for pharmacy and nursing in-services.
• Inclusion of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) each month.
• Publication of a monthly drug class review.

Main Results:

• Subscribers receive print and online access to monographs.
• Monographs are customizable to facility needs.
• The service includes specific examples like November 2014 topics: suvorexant, idelalisib, belinostat, C1 esterase inhibitor, and ledipasvir, with a DUE/MUE on suvorexant.

Conclusions:

• The Formulary Monograph Service offers a valuable, comprehensive resource for P&T Committees and healthcare facilities.
• The integrated approach of monographs, summaries, and DUE/MUEs supports evidence-based medication management.
• The service facilitates informed decision-making regarding drug formulary inclusion and utilization.